Ke Zhang’s lab in Boston is building tiny bottlebrush-shaped molecules that could change how we treat diseases like cancer, Alzheimer’s, and epilepsy. These microscopic carriers are designed to deliver gene-targeting drugs exactly where they’re needed—like a molecular ZIP code guiding medicine through the body’s maze of cells and tissues.
Most medicines today work on proteins already causing harm. But a new class of drugs called oligonucleotides goes one step further back. Made from snippets of DNA or RNA, they can stop harmful proteins from being made in the first place—or help cells produce ones they’re missing. The problem has never been the drug’s potential. It’s been delivery. “Knowing what gene to target is only part of the problem,” says Zhang, a chemistry professor at Northeastern University. “The other part is getting the drug to the right place in the right cells.”
The human body doesn’t make it easy. Cell membranes block large, charged molecules like oligonucleotides. And the kidneys quickly filter them out of the bloodstream. To overcome this, Zhang’s team created bottlebrush polymers—long molecular chains with a backbone and thick bristles that shield the drug. These bristles aren’t just protective; they add size, helping the drug stay in circulation longer by evading kidney filtration.
But staying in the blood isn’t enough. The drug must also find its target. Some delivery methods use antibodies as homing devices, but those can be imprecise—like using the same key for multiple locks. Zhang’s breakthrough is simpler: the packaging itself carries the address. A short sequence of chemical building blocks built into the polymer acts like delivery instructions, steering the drug toward specific tissues. In early tests, this approach successfully guided molecules to their intended destinations, a leap toward treating diseases that currently have no cure.
This isn’t just lab curiosity. Diseases like Alzheimer’s, certain cancers, and severe seizure disorders are rooted in faulty genetic instructions. If doctors can reach the cells where those errors live, they may finally be able to correct them. Zhang’s bottlebrush molecules are still in development, but they represent a promising path forward—one where medicine doesn’t just manage symptoms, but fixes problems at their source. And with every new design, the dream of precision medicine gets a little closer to reality.